KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Cash & Equivalents (2016 - 2025)

Ionis Pharmaceuticals has reported Cash & Equivalents over the past 17 years, most recently at $372.3 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $372.3 million for Q4 2025, up 53.78% from a year ago — trailing twelve months through Dec 2025 was $372.3 million (up 53.78% YoY), and the annual figure for FY2025 was $372.3 million, up 53.78%.
  • Cash & Equivalents for Q4 2025 was $372.3 million at Ionis Pharmaceuticals, up from $338.3 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for IONS hit a ceiling of $869.2 million in Q4 2021 and a floor of $242.1 million in Q4 2024.
  • Median Cash & Equivalents over the past 5 years was $350.5 million (2023), compared with a mean of $405.7 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 118.57% in 2021 and later crashed 68.19% in 2022.
  • Ionis Pharmaceuticals' Cash & Equivalents stood at $869.2 million in 2021, then crashed by 68.19% to $276.5 million in 2022, then skyrocketed by 44.41% to $399.3 million in 2023, then tumbled by 39.37% to $242.1 million in 2024, then skyrocketed by 53.78% to $372.3 million in 2025.
  • The last three reported values for Cash & Equivalents were $372.3 million (Q4 2025), $338.3 million (Q3 2025), and $297.3 million (Q2 2025) per Business Quant data.